Eli Lilly to Acquire Engage Bio for $202M to Bolster Genetic Medicines Pipeline
Eli Lilly has agreed to acquire Engage Bio for up to $202 million in cash, adding its preclinical non-viral Tethosome DNA delivery platform to Lilly’s genetic medicines portfolio. Engage’s lipid nanoparticle-delivered DNA payload combined with an mRNA-encoded sequence aims to boost expression and enhance localisation for new genetic therapies.
1. Deal Overview
Eli Lilly has agreed to purchase Engage Bio for up to $202 million in cash, securing exclusive rights to the preclinical Tethosome non-viral DNA delivery platform. The transaction marks Lilly’s eighth acquisition since January 2026 as it expands its footprint in genetic medicine.
2. Tethosome Delivery Platform
Engage’s Tethosome system pairs a lipid nanoparticle-delivered DNA payload with an mRNA-encoded sequence, designed to overcome tolerability, potency and redosability challenges. This dual-modal approach may enhance gene expression and localisation compared with existing non-viral delivery methods.
3. Lilly’s M&A Strategy
Following major purchases of Ajax Therapeutics for $2.3 billion, CrossBridge Bio for $300 million and Centessa Pharmaceuticals for $7.8 billion, Lilly is aggressively bolstering its pipeline. The Engage acquisition complements recent AI-focused pacts and underscores Lilly’s push to lead in genetic therapies.